MURINE STRAIN DIFFERENCES IN METABOLISM AND BLADDER TOXICITY OF CYCLOPHOSPHAMIDE

被引:29
|
作者
FRAISER, L [1 ]
KEHRER, JP [1 ]
机构
[1] UNIV TEXAS,COLL PHARM,DIV PHARMACOL & TOXICOL,AUSTIN,TX 78712
关键词
CYCLOPHOSPHAMIDE; HEMORRHAGIC CYSTITIS; STRAIN DIFFERENCE; METABOLISM; BLADDER INJURY; ACROLEIN;
D O I
10.1016/0300-483X(92)90007-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cyclophosphamide (CP) undergoes metabolic activation, generating phosphoramide mustard and acrolein which are believed to be responsible for the cytostatic and toxic effects, respectively. In this study, CP-induced bladder toxicity (hemorrhagic cystitis) was found to be significantly greater in the ICR than the C57BL/6N (C-57) strain of mice. Strain differences exist in the distribution of CP metabolites to the bladder, as evidenced by consistently higher levels of acrolein equivalents measured in the urine of the sensitive ICR strain. These differences may arise from strain variation in the oxidative metabolism of CP by the mixed-function oxidase system. However, intrinsic factors within the bladder may also be involved in the resistance exhibited by C-57 mice. Support for this hypothesis is provided by the significant increase in hemorrhagic response and permeability of ICR compared to C-57 bladders exposed to equivalent levels of acrolein by intravesicle instillation. Basal protein thiol levels were higher in C-57 than in the ICR strain. However, the effects of acrolein on protein thiol content did not correlate with toxicity suggesting that these groups are not the critical targets for CP-induced bladder injury.
引用
收藏
页码:257 / 272
页数:16
相关论文
共 50 条
  • [1] MURINE STRAIN DIFFERENCES IN PULMONARY BLEOMYCIN METABOLISM
    FILDERMAN, AE
    LAZO, JS
    [J]. BIOCHEMICAL PHARMACOLOGY, 1991, 42 (01) : 195 - 198
  • [2] INFLUENCE OF STRAIN DIFFERENCES IN MICE ON THE METABOLISM AND TOXICITY OF BENZENE
    LONGACRE, SL
    KOCSIS, JJ
    SNYDER, R
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 1981, 60 (03) : 398 - 409
  • [3] METABOLISM AND PULMONARY TOXICITY OF CYCLOPHOSPHAMIDE
    PATEL, JM
    [J]. PHARMACOLOGY & THERAPEUTICS, 1990, 47 (01) : 137 - 146
  • [4] CYCLOPHOSPHAMIDE METABOLISM .11. INFLUENCE OF DIURETICS ON URINARY GENERAL BASE CATALYTIC ACTIVITY AND CYCLOPHOSPHAMIDE-INDUCED BLADDER TOXICITY
    SLADEK, NE
    SMITH, PC
    BRATT, PM
    LOW, JE
    POWERS, JF
    BORCH, RF
    COVENEY, JR
    [J]. CANCER TREATMENT REPORTS, 1982, 66 (11): : 1889 - 1900
  • [5] CYCLOPHOSPHAMIDE-INDUCED BLADDER TOXICITY IN WEGENERS GRANULOMATOSIS
    STILLWELL, TJ
    BENSON, RC
    DEREMEE, RA
    MCDONALD, TJ
    WEILAND, LH
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (04): : 465 - 470
  • [6] Assessment of murine bladder permeability with fluorescein: Validation with cyclophosphamide and protamine
    Eichel, L
    Scheidweiler, K
    Kost, J
    Shojaie, J
    Schwarz, E
    Messing, E
    Wood, R
    [J]. UROLOGY, 2001, 58 (01) : 113 - 118
  • [7] STRAIN DIFFERENCES IN PRODUCTION OF MURINE INTERFERONS
    TYRING, SK
    LEFKOWITZ, SS
    [J]. PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1980, 164 (04): : 519 - 523
  • [8] ROLE OF GLUTATHIONE IN CYCLOPHOSPHAMIDE METABOLISM-RELATED TOXICITY
    HIPKENS, J
    GURTOO, H
    AMBRUS, J
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 9 - 9
  • [9] CYCLOPHOSPHAMIDE-INDUCED BLADDER TOXICITY IN PATIENTS WITH WEGENERS GRANULOMATOSIS
    TALARWILLIAMS, C
    HIIAZI, Y
    WALTHER, M
    HALLAHAN, CW
    KERR, GS
    HOFFMAN, GS
    LUBENSKY, I
    FAUCI, AS
    SNELLER, MC
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (09): : 1425 - 1425
  • [10] BLADDER TOXICITY WITH CHRONIC ORAL CYCLOPHOSPHAMIDE THERAPY IN NONMALIGNANT DISEASE
    APTEKAR, RG
    ATKINSON, JP
    DECKER, JL
    WOLFF, SM
    CHU, EW
    [J]. ARTHRITIS AND RHEUMATISM, 1973, 16 (04): : 461 - 467